Zevra Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 69
- Market Cap
- $379.3M
- Website
- http://zevra.com
- Introduction
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH
- Conditions
- Idiopathic Hypersomnia
- Interventions
- Drug: SerdexmethylphenidateOther: Placebo
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Zevra Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT05668754
- Locations
- 🇺🇸
Clinical Neurophysiology Services PC, Sterling Heights, Michigan, United States
🇺🇸Neurotrials Research, Inc, Atlanta, Georgia, United States
🇺🇸Angels Clinical Research, Miami, Florida, United States
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
- Conditions
- ADHD
- Interventions
- Drug: KP415 oral capsule
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Zevra Therapeutics
- Target Recruit Count
- 282
- Registration Number
- NCT03460652
- Locations
- 🇺🇸
Innovative Clinical Research, Inc., Lauderhill, Florida, United States
🇺🇸MCB Clinical Research Centers, Colorado Springs, Colorado, United States
🇺🇸Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
- Conditions
- ADHD
- Interventions
- Drug: Placebo oral capsuleDrug: KP415 oral capsule
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Zevra Therapeutics
- Target Recruit Count
- 155
- Registration Number
- NCT03292952
- Locations
- 🇺🇸
Meridien Research, Maitland, Florida, United States
🇺🇸Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nevada, United States
🇺🇸Bayou City Research, Ltd., Houston, Texas, United States